Complete pathological response has been recognised as an important predictor of long-term remission, meaning it is often a key endpoint in clinical trials. Dr Bernardo Rapoport talks to touchONCOLOGY about complete pathological response and which clinical characteristics, such as molecular subtype and Ki-67, are associated with pathological response. Ki-67 is an important prognostic factor, not only in breast cancer but also in neoendocrine tumours, prostate cancer, and brain tumours. Dr Rapoport explains how the expression of Ki-67 translates to cell replication and how it can be an indicator of treatment response.
1. What is the definition of complete pathological response? (0:11)
2. Why has complete pathological response become such an important endpoint in trials of neoadjuvant chemotherapy in early breast cancer? (1:09)
3. What were the most important prognostic factors associated with complete pathological response in your recent study? (2:03)
4. What is the Ki-67 protein and what is its prognostic significance in early breast cancer subtypes? (3:09)
5. What future studies are planned in the investigation of this potential biomarker? (4:30)
Speaker disclosures: Bernardo Rapoport has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Breast Cancer
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Javier Cortes, SABCS 2020 – Pembrolizumab in Triple-negative Breast Cancer
touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!